• Glaxosmithkline plc, of London, was granted breakthrough-therapy designation by the FDA for drisapersen for the potential treatment of patients with Duchenne's muscular dystrophy. Phase II U.S. and rest-of-world Phase III data on drisapersen are expected to report in the third and fourth quarters, respectively, of this year.